In the rapidly evolving landscape of global health, cancer screening remains a critical front in the battle against one of the most devastating diseases worldwide. The ASEAN region, comprising diverse nations with varying healthcare infrastructures, presents a unique challenge and opportunity in this regard. A recent comprehensive scoping review published in BMC Cancer sheds new light on the current state of cancer screening programs across Southeast Asia, with a pioneering focus on the integration of artificial intelligence (AI) technologies within these efforts.
Cancer continues to pose a significant public health challenge across the ASEAN member states, where demographic, socioeconomic, and infrastructural disparities influence health outcomes. Despite advances in medical technology, cancer screening programs vary widely in terms of their methodology, target populations, and screening intervals, illustrating a fragmented approach to what must be a coordinated effort to improve early detection. This patchwork of strategies often undermines the efficacy of early diagnosis, which is critical to improving survival rates.
The study, authored by Tun and colleagues, undertakes a thorough analysis of cancer screening frameworks throughout the ASEAN region, paying particular attention to how artificial intelligence is being utilized to enhance screening accuracy, efficiency, and ultimately, clinical outcomes. AI’s potential to revolutionize screening through advanced pattern recognition and predictive analytics could offer transformative benefits, especially in resource-limited settings prevalent in parts of Southeast Asia.
Leveraging PRISMA-ScR guidelines, the research team meticulously compiled data from government health ministries, official national cancer control guidelines, and peer-reviewed literature utilizing extensive database searches through PubMed, Scopus, and Google Scholar. The review specifically included studies conducted from 2019 to mid-2024, ensuring a contemporary overview of both traditional screening programs and cutting-edge AI applications. This rigor allows for an inclusive perspective that bridges policy, clinical practice, and emerging technology.
The findings reveal a stark dichotomy within ASEAN cancer screening protocols. Countries like Myanmar, Laos, Cambodia, Vietnam, Brunei, the Philippines, Indonesia, and Timor-Leste have primarily adopted opportunistic screening approaches. This model relies heavily on patient-initiated testing or incidental detection during unrelated healthcare visits, leading to inconsistent coverage and variable diagnostic yield. Conversely, more developed systems in Singapore, Malaysia, and Thailand demonstrate predominantly organized screening programs characterized by systematic population-wide invitations, standardized intervals, and data-driven follow-up mechanisms.
Cervical cancer screening emerges as the most widespread across both opportunistic and organized models, reflecting successful implementation of both Pap smear cytology and human papillomavirus (HPV) testing in several countries. Other cancers under active screening scrutiny include breast, colorectal, hepatic, lung, and oral cancers — with varying degrees of emphasis depending on local prevalence and resource availability.
Among the 14 studies included in the scoping review, breast cancer screening was the most frequently addressed, reflecting global trends given its high incidence and survival outcomes affected drastically by early detection. The researchers noted that AI’s integration into cancer screening workflows is in varying phases: half of the studies evaluated prospectively in clinical settings, over a third were silent trials where AI runs alongside human screening without affecting clinical decisions, and the remainder focused on exploratory model development aimed at future deployment.
AI applications ranged from image-based diagnostics, such as mammography and colonoscopy interpretation aided by deep learning algorithms, to predictive risk stratification models that customize screening intervals and protocols based on individualized patient data. The initial results demonstrate that AI not only improves sensitivity and specificity of cancer detection but also holds promise in reducing operational costs by automating labor-intensive tasks and minimizing unnecessary biopsies or follow-up procedures.
Despite these advances, the review underscores several persistent challenges. In many ASEAN countries, limited digital infrastructure, scarcity of high-quality annotated datasets for training AI models, and regulatory hurdles stall the full-scale deployment of AI-centric screening. Moreover, the heterogeneity of healthcare systems and sociocultural factors influence screening uptake and acceptance of AI interventions, highlighting the need for tailored implementation strategies.
The conclusion drawn from this comprehensive scoping review advocates for a shift towards more organized, standardized cancer screening programs aligned with the World Health Organization’s 2030 targets. Such programs must adopt regular screening intervals, prioritize appropriate age groups, and ensure equitable access across varied populations. Integrating AI technologies judiciously can catalyze this transformation by enabling precision medicine, facilitating early detection, and optimizing resource allocation.
Incorporating AI into cancer screening in countries like Singapore, Malaysia, Vietnam, Thailand, and Indonesia has already demonstrated promising enhancements in diagnostic accuracy and workflow efficiency. These implementations point towards a future where AI-supported screening could significantly reduce cancer-related mortality by enabling timely interventions supported by robust data analytics and machine learning.
The review also highlights the critical role of interdisciplinary collaboration spanning clinical experts, data scientists, policymakers, and international stakeholders to establish best-practice guidelines for AI integration. Robust validation studies, ethical frameworks addressing patient privacy, and capacity-building initiatives focusing on technical expertise will be vital components to scale AI innovations sustainably.
As ASEAN nations continue to grapple with the dual burden of communicable and noncommunicable diseases, advancing cancer screening through AI offers a beacon of hope. The synergy of emerging technology and strengthened public health infrastructure could unlock unprecedented potential in cancer prevention and control, driving progress towards healthier futures for millions.
While the transformative power of AI is evident, the path to widespread adoption remains complex and nuanced. Future research should focus on longitudinal, multicenter studies to understand real-world impact and guide policies for equitable AI deployment in diverse clinical settings. Additionally, patient and provider education will be critical to foster trust and acceptance of AI-assisted cancer screening paradigms.
The exploration of AI’s role in cancer screening within ASEAN is not merely a technological endeavor but a healthcare imperative reflective of regional needs and global ambitions. This scoping review lays a foundational roadmap for future innovations, emphasizing that technological progress must be accompanied by systems-level integration and ethical stewardship.
The compelling data and insights emerging from this research signify a paradigm shift where AI augments human expertise, amplifying the reach and efficacy of cancer screening programs. By closing existing gaps in early detection and enhancing diagnostic confidence, AI-enabled screening can become an integral pillar in the pursuit of cancer control across Southeast Asia and beyond.
In sum, the thoughtful convergence of digital intelligence with organized healthcare delivery is poised to redefine cancer screening landscapes. The ASEAN region stands at the cusp of this transformation, where informed policy, strategic investment, and collaborative innovation will determine the trajectory of cancer prevention for generations.
Subject of Research: Artificial intelligence application and evaluation in cancer screening programs across ASEAN countries.
Article Title: Artificial intelligence utilization in cancer screening program across ASEAN: a scoping review
Article References:
Tun, H.M., Rahman, H.A., Naing, L. et al. Artificial intelligence utilization in cancer screening program across ASEAN: a scoping review. BMC Cancer 25, 703 (2025). https://doi.org/10.1186/s12885-025-14026-x
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14026-x
Tags: AI in cancer screeningArtificial Intelligence in MedicineASEAN healthcare challengescancer screening innovationscancer screening program effectivenesscomprehensive scoping review on cancerdemographic impacts on health outcomesearly cancer detection strategieshealthcare disparities in Southeast Asiaimproving cancer survival ratesintegrating AI in healthcaretechnology in public health
